New drug combo aims to boost immune attack on tough melanoma
NCT ID NCT06940739
First seen Dec 12, 2025 · Last updated May 07, 2026 · Updated 21 times
Summary
This early-stage trial tests a new drug (IOV-3001) combined with an immune cell therapy (lifileucel) in adults with advanced melanoma that has stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can help control the disease. About 42 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Greenslopes Private Hospital
RECRUITINGGreenslopes, Queensland, 4120, Australia
-
SCRI Oncology Partners- Denver
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.